Netarsudil/latanoprost

{{Short description|Combination drug}}

{{Use American English|date=July 2020}}

{{Use dmy dates|date=June 2020}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| type = combo

| image =

| width =

| alt =

| caption =

| component1 = Netarsudil

| class1 = Rho kinase inhibitor

| component2 = Latanoprost

| class2 = Prostaglandin F2α analogue

| tradename = Rocklatan, Roclanda

| Drugs.com = {{drugs.com|ppa|netarsudil-and-latanoprost}}

| MedlinePlus =

| DailyMedID = Netarsudil and latanoprost

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = Eye drops

| ATC_prefix = S01

| ATC_suffix = EE51

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment =

| legal_EU = Rx-only

| legal_EU_comment = {{cite web | title=Roclanda EPAR | website=European Medicines Agency (EMA) | date=9 November 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/roclanda | access-date=22 January 2021}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

{{cite web | title=Roclanda Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1502.htm | access-date=3 March 2023}}

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| PubChem =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG = D11558

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

}}

Netarsudil/latanoprost, sold under the brand name Rocklatan among others, is a fixed-dose combination medication use to treat elevated intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.{{cite web | title=Rocklatan- netarsudil and latanoprost ophthalmic solution, 0.02%/0.005% solution/ drops | website=DailyMed | date=10 March 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1d71f41-be06-4a08-94d4-e352198f09c2 | access-date=2 June 2020}} It contains netarsudil mesylate and latanoprost. It is applied as eye drops to the eyes.

The most common side effects include conjunctival hyperaemia (red eye), pain at the site where the medicine was applied, cornea verticillata (deposits in the cornea, the transparent layer in front of the eye that covers the pupil and iris), pruritus (itching of the eye), erythema (reddening) and discomfort in the eye, increased lacrimation (watery eyes), and conjunctival haemorrhage (bleeding in the surface layer of the eye).

Netarsudil/latanoprost was approved for medical use in the United States in March 2019,{{cite web | title=Drug Approval Package: Rocklatan Ophthalmic Solution | website=U.S. Food and Drug Administration (FDA) | date=20 November 2019 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208259Orig1s000TOC.cfm | archive-url=https://web.archive.org/web/20200603021659/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208259Orig1s000TOC.cfm | url-status=dead | archive-date=3 June 2020 | access-date=2 June 2020}} and in the European Union in January 2021.